|
|
|
| The role of the polymorphism of CYP2C9 in Warfarin anticoagulation therapy for patients with atrial fibrillation |
| LYU You YANG Jiefu |
| Department of Caidiology, Beijing Hospital, Beijing 100730, China |
|
|
|
Abstract Objective To investigate the significance of CYP2C9 gene polymorphism in Warfarin anticoagulation therapy for patients with atrial fibrillation, in order to explore the causes of Warfarin individual difference. Methods The 3rd and 7th exon of CYP2C9 in 100 patients with atrial fibrillation given Warfarin anticoagulation therapy in Beijing Hospital were detected by PCR and restriction enzyme digestion. The genotype and allelic frequencies were calculated and patients information, coagulation function and the individual Warfarin dosage requirements were recorded. Results In this group of patients with atrial fibrillation given Warfarin anticoagulation therapy, two kinds of allele were detected: CYP2C9*1 and CYP2C9*3, the frequency of *1 allele and *3 allele was 96% and 4% respectively. CYP2C9*1/*1 was the most common genotype, with the frequency of 92%. The frequency of CYP2C9*1/*3 was 8% in these 100 patients. After similar target INR range (2.0-3.0) achieved, variant CYP2C9*1/*3 homozygotes or heterozygotes required lower daily mean maintain doses [(2.14±0.55) mg] than wild-type CYP2C9*1/*1 patients did [(3.17±0.74) mg], with statistically significant difference (P < 0.05). Conclusion Polymorphism of CYP2C9 is associated with Warfarin dose requirements in patients with atrial fibrillation, which is partly the factor causing Warfarin individual difference .
|
|
|
|
|
|
[1] Hirshj，Fuster V，Ansell J，et al. American heart association/American college of cardiology foundation guide to warfarin therapy [J]. Circulation，2003，107（5）：1692-1711.
[2] Aronow WS. Management of atrial fibrillation in the elderly [J]. Minerva，2009，100（12）：3-24.
[3] Zaidenstein R，Eyal S，Efrati S. Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants [J]. Pharmacoepidemiol Drug Safety，2002， 11（9）：235–238.
[4] Yoon YR，Shon JH，Kim MK，et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population [J]. Br J Clin Pharmacol，2001，51（3）：277-280.
[5] Allabi C，Galaj L，Horsmansy，et al. Functional impact of CYP2C9*5，CYP2C9*6，CYP2C9*8，and CYP2C9*11 in viv among black Africans [J]. Clin Pharmacol Ther，2004， 76（2）：113-118.
[6] Yin T，Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives [J]. Thromb Res，2007，120（10）：1-10.
[7] Sanderson S，Emery J，Higgins J. CYP2C9 gene variants，drug dose，and bleeding risk in warfarin-treated patients：a HuGEnet systematic review and meta-analysis [J]. Genet Med，2005，17（7）：97-104.
[8] Chern HD，Zeng TH，Fu YP，et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese [J]. Clin Chim Acta，2006，367（8）：108-113.
[9] Rost S，Fregin A，Ivaskevicius V，et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type [J]. Nature，2004，42（7）：537-541.
[10] Li T，Lang LA，Li X，et al. Polymorphisms in the VKORC1 gene are strongly association with warfarin dosage requirements in patients receiving anticoagulation [J]. J Med Genet，2006，43（4）：740-744.
[11] Reiner MJ，Reiner AP，Gage BF，et al. Effect of VKORC1 haplotypes on transcrip tional regulation and warfarin dose [J]. N Engl J Med，2005，352（5）：2285-2293.
[12] Miao L，Yang J，Huang C，et al. Contribution of age，body weight，and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin：proposal for a new dosing regimen in Chinese patients [J]. Eur J Clin Pharmacol，2007， 69（13）：1135-1141.
[13] Yuan HY，Chen JJ，Lee MT，et al. A novel functional VKORC1 promoter polymorphism is association with inter-individual and inter-ethnic differences in warfarin sensitivity [J]. Hum Mol Genet，2005，14（3）：1745-1751.
[14] D′Andrea G，D′Ambrosio RL，Di Perna P，et al. A polymorphism in the VKORC1 gene is association with an interindividual variability in the dose- anticoagulant effect of warfarin [J]. Blood，2005，105（11）：645-649.
[15] 戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志，2003，31（11）：913-916.
[16] Oates A， Jackson PR，Austin CA，et al. A new regimen for starting warfarin therapy in out-patients [J]. Br J Clin Pharmacol，1998，46（9）：157-161.
[17] Kamali F，Khan TI，King BP，et al. Contribution of age，bodysize，and CYP2C9 genotype to anticoagulant response to warfarin [J]. Clin Pharmacol Ther，2004，75（12）：204-212.
[18] Wu AH，Wang P，Smith A，et al. Dosing algorithm forwarfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population comparison with other equations [J]. Pharmacogenomics，2008，9（23）：169-178.
[19] Klein TE，Altman RB，Eriksson N，et al. Estimation of the warfarin dose with clinical and pharmacogenetic data [J]. N Engl J Med，2009，360（8）：753-764. |
|
|
|
